NCT05949125
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05949125
Title Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AvenCell Europe GmbH
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | DEU

Facility Status City State Zip Country Details
Universitätsklinikum Ulm RECRUITING Ulm Baden-Wurttemberg 89081 Germany Details
Klinikum der Universität München RECRUITING Munich Bavaria 81377 Germany Details
Universitätsklinikum Würzburg RECRUITING Würzburg Bavaria 97080 Germany Details
Universitätsklinikum Marburg RECRUITING Marburg Hesse 35032 Germany Details
Universitätsklinikum Dresden RECRUITING Dresden Saxony 01307 Germany Details
Charité Universitätsmedizin Berlin RECRUITING Berlin 13353 Germany Details
Universitätsklinikum Köln RECRUITING Cologne 50937 Germany Details
Medizinische Hochschule Hannover RECRUITING Hanover Germany Details
Erasmus University Medical Center RECRUITING Rotterdam Gelderland 3015 Netherlands Details
Amsterdam University Medical Center NOT_YET_RECRUITING Amsterdam HV 1081 Netherlands Details
University Medical Center Groningen (UMCG) NOT_YET_RECRUITING Groningen RB Groningen 9700 Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field